Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.19.3
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 24 Months Ended 57 Months Ended 94 Months Ended
Oct. 21, 2019
Oct. 12, 2017
Sep. 30, 2018
Jul. 31, 2018
May 31, 2016
Jan. 31, 2015
Dec. 31, 2010
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Mar. 31, 2013
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Upfront payment from development and license agreement   $ 6,000,000                          
Milestone revenue recognized               $ 5,800,000   $ 14,300,000 $ 0        
Contract liability                 $ 34,200,000   34,200,000 $ 34,200,000   $ 91,100,000  
VFMCRP | Development and License Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
License revenue, initial payment         $ 50,000,000                    
VFMCRP | Regulatory Milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Additional milestone payment       $ 2,000,000.0                      
Additional milestone payment to be received         35,000,000                    
VFMCRP | Launch and Sales-based Milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Additional milestone payment to be received         195,000,000                    
VFMCRP | Exclusive Option                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Additional milestone payment to be received         $ 555,000,000                    
Pfizer | Products                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone revenue recognized                       0      
Additional milestone payment to be received           $ 275,000,000.0                  
Non-refundable and non-creditable upfront payment           295,000,000.0                  
Contract liability                 28,000,000.0   $ 28,000,000.0 $ 28,000,000.0      
Tesaro                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone revenue recognized                 $ 0 $ 0          
Additional milestone payment             $ 85,000,000                
Upfront payment under license agreements             $ 6,000,000.0                
Milestone payment received                         $ 30,000,000    
Period from first commercial sale             12 years                
Written termination threshold             3 months                
Minimum | Pfizer | Products                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Each milestone payment           20,000,000.0                  
Maximum | Pfizer | Products                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Each milestone payment           $ 90,000,000.0                  
Pharmsynthez                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Ownership percentage, equity method                 9.00%   9.00% 9.00%      
Phio Pharmaceuticals                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Maximum milestone payments to be received                             $ 50,000,000.0
Phase Two Initiation                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Upfront payment from development and license agreement     $ 6,000,000                        
Regulatory and Development                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone payment from development and license agreement   31,000,000                          
Sales Revenue                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone payment from development and license agreement   $ 75,000,000                          
Subsequent Event | Pfizer | Products                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Annual height velocity at point in time 12 months